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Purpose/Objective: Here we report the prospectively 
documented short- and long-term health-related quality of 
life (HRQoL) of a large cohort of patients with advanced 
laryngeal cancer. The patients were treated in a randomized 
trial comparing accelerated radiotherapy with carbogen and 
nicotinamide (ARCON) against accelerated radiotherapy alone 
(AR). 
Materials and Methods: Of 345 patients with cT2-4 laryngeal 
cancer, 174 were randomly assigned to AR and 171 to ARCON. 
HRQoL was assessed using the European Organisation for 
Research and Treatment of Cancer (EORTC) QoL 
Questionnaire-C30 (QLQ-C30) and the Head&Neck cancer 
module (QLQ-H&N35) at baseline, at completion of 
radiotherapy and at 6, 12, and 24 months post-baseline. 
Tumor- and patient related factors with potential impact on 
quality of speech and swallowing were analyzed separately. 
Data were analyzed two years after inclusion of the last 
patient. 
Results: Compliance with completion of questionnaires at 
different time-points was high (AR: 60-79%; ARCON 70-81%). 
Significant clinical impact (>10 effect-points) was observed 
for nearly all items of the QLQ-C30 and QLQ-H&N35 between 
baseline and end of treatment. At 6 months, scores returned 
to baseline level for all items with exception of dry mouth, 
sticky saliva, taste- and smell perception. No difference in 
HRQoL score between AR and ARCON was observed at any of 
the time points. The rate of patients reporting 'quite a bit' or 
'very much' complaints of dry mouth, sticky saliva, or changes 
in taste- and smell perception for AR vs ARCON is limited to 
26% vs 33%, 20% vs 23% and 20% vs 17% at 2 years, 
respectively. At 2 years from diagnosis, the majority of 
patients treated by AR vs ARCON, have 'not at all' or 'a little' 
complaints of swallowing (77% vs 81%; P=.37) or speech (64 vs 
63%, P=.51). Long-term function of speech and swallowing for 
patients presenting with T4 tumors was not impaired 
compared to T2-T3 tumors. The use of a feeding tube at 2 
years from diagnosis was limited to 6% vs 4% of AR vs ARCON 
patients, respectively. 
Conclusions: With ARCON, a high local control (± 80%) and a 
significantly improved regional control rate are observed 
while maintaining excellent speech and swallowing function 
for the majority of patients, independent of T-stage. Long 
term dry mouth, sticky saliva and changes in taste and smell 
perception are limited to one quarter of patients and not 
different between both treatment arms. 
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Purpose/Objective: To determine the predictors and 
patterns of regional recurrence in patients treated with 
stereotactic body radiotherapy (SBRT) for primary lung 
cancers. 
Materials and Methods: Patients with primary lung cancer 
treated with SBRT were identified from a multi-institutional 
(5) database of 965 cases. Patients with previous lung cancer 
or multiple lung tumors (231) were excluded leaving 734 
analyzable patients. Details of patient factors, treatment 
specifics, toxicity and clinical outcomes were extracted from 
the database. All events were calculated from the end of 
radiotherapy. Estimates of local (LR), regional (RR), and 
distant recurrence (DR) were calculated using the competing 
risk method. Cause specific (CSS) and overall survival (OS) 
were calculated using the Kaplan-Meier method. Details of 
locations and number of simultaneous regional failures were 
categorized by lymph node (LN) anatomic level. 
Results: The median follow-up time was 1.4 years (0.1-14.8 
years). The median age was 76 years (42-94), 367(50%) were 
male, 644 (88%) tumors were peripheral per RTOG 0236 and 
43 (6%) had mediastinal staging with EBUS/mediastinoscopy. 
Tumor location was right upper lobe (RUL) 235 (32%), right 
middle lobe (RML) 52 (7%), right lower lobe (RLL) 86 (12%), 
left upper lobe (LUL) 260 (35%), left lower lobe (LLL) 79 (11%) 
and missing 21 (3%). All patients had a staging PET scan. The 
median maximum tumor dimension was 2.3cm (0.7- 8.5cm). 
476 had pathological proven cancer. The median RT dose was 
54 Gy (18-64) and the median number of fractions was 3 (1-
10). There were 64 RR. The 2 and 5 year recurrence rates 
were LR 5.6% and 8.3%, RR 9.0% and 13.4%, and DR 14.6% and 
19.0% respectively. On univariable analysis (UVA) tumor 
dimension (p=0.3), tumor baseline SUV (p=0.1), histology 
(p=0.3), RT dose (p=0.5), tumor location (p=0.8) and gender 
(p=0.6) were not correlated with RR. On the biopsy proven 
cohort (n=476) the 2 and 5 year recurrence rates were LR 
7.6% and 11.0%, RR 9.5% and 12.9%, and DR 17.9% and 21.5% 
respectively. On UVA tumor baseline SUV (p=0.03) was 
correlated with RR. There were 181 simultaneous sites of RR. 
16 patients had single station RR in station 12R (1RUL), 
station 10R (2RUL, 2RLL), station 10L (1LLL), station 7 (2RUL, 
2RLL, 1 LLL), station 4R (1RUL, 1RLL), station 2R (1RUL) and 
station 5 (1LLL). The pattern of LN failure was station 10 
n=23 (13%), station 7 n=70 (39%), station 4 n=25 (14%), 
station 2 n=10 (6%) and other stations n=53 (29%). The most 
common RR levels were stations 4 & 7 for RUL and LUL, 
stations 4, 5, 7 & 10 for LLL tumors and stations 7&10 for RML 
and RLL tumors. 
Conclusions: Baseline SUV is correlated with RR. Stations 10, 
7 and 4 were most common stations for RR. These patterns of 
recurrence may guide nodal staging procedures prior to SBRT.  
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Purpose/Objective: According to current evidence 
radiotherapy (RT) should be delivered to 50% of all cancer 
patients. In order to use this benchmark value to plan for RT 
capacity (i.e. linear accelerators and staff) in a given 
population it is necessary to account also for the proportion 
of repeat RT courses given after the first radiation 
treatment. The aim of the study was to determine the 
patterns of re-treatment for the cohort of patients who 
received their first RT course in 2009 in a RT department 
with a stable catchment area of 1.25 million inhabitants.  
Materials and Methods: From the institutional RT database 
the following information was retrieved for all new RT 
patients in 2009: Start date of first treatment course and all 
subsequent courses, number of fractions and RT technique in 
each course, cancer diagnosis, age, and intention of the 
treatment (curative including SBRT and prophylactic RT or 
palliative). The number of patients receiving their first RT 
course in 2009 (#first courses) and the total number of re-
irradiation courses delivered until now (#re-irradiation 
courses) were determined and the mean number of re-
treatments was calculated as #re-irradiation courses /#first 
courses.  
Results: The median age at first course was 65 y (range 5 mo-
95 y). Total #first courses in 2009 were 2666 (1691 curative 
RT and 875 palliative RT). Breast cancer (46%), prostate 
cancer (14%) and head and neck cancer (9%) were the three 
most common diagnoses for patients treated with curative 
intent in their first course, whereas lung cancer (38%), 
prostate cancer (10%) and breast cancer (8%) were the most 
common diagnoses when the intent was palliative. Total #re-
irradiation courses were 667 resulting in a mean number of 
re-treatments of 0.25 per patient (664/2666). The proportion 
of patients re-treated at least once was 18% (475/2666 
patients), and three or more courses were given to 133 
patients (5%). The maximum number of courses was 8 (one 
patient). The median time between the first and the second 
course was 553 and 144 days for patients treated initially 
with curative intent and palliative intent, respectively. The 
intent at the second treatment course was palliative for 78% 
of the patients and curative for 22% of the patients; 29 
patients were treated with curative intent in both the first 
and second course. Breast cancer was the most common 
diagnosis in that group with 13 patients either treated for a 
second breast cancer or another cancer. In total 36 of the 
2666 patients (1.3%) were later treated with RT for a new 
cancer diagnosis.  
Conclusions: With a follow up period of 5 years the re-
irradiation proportion was found to be 25% and the 
proportion of patients re-treated was 18%; these numbers are 
in good agreement with other published series and will be 
useful for the future planning of radiotherapy services.  
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Purpose/Objective: During 2009-2011, external peer review 
clinical audits for breast cancer radiotherapy was carried out 
at nine radiotherapy centres in Norway. The purpose was to 
assess compliance with the national radiotherapy guidelines 
regarding treatment planning for post-operative left sided 
breast cancer. All radiotherapy departments volunteered to 
take part in the audits. The audits were organized as a joint 
project between the Norwegian Breast Cancer Group (NBCG) 
and the quality assurance group in radiotherapy (KVIST) at 
the Norwegian Radiation Protection Authority. 
Materials and Methods: The audit topic was post-operative 
left sided breast cancer radiotherapy, focusing on indication 
and radiotherapy treatment planning. The audit standard was 
the national guidelines for breast cancer treatment 
(developed by NBCG). A set of audit criteria was developed 
to evaluate the clinical practice against the national 
guidelines. A total of 180 treatment files were audited by 
auditor groups composed of oncologists, medical physicists 
and RTTs. The audit findings were grouped to analyse the 
degree of guideline compliance for indication, treatment 
technique, delineation of treatment volumes and organs at 
risk, and dose related parameters. 
Results: Over all, the auditors evaluated the indication, 
delineation, treatment planning qualitatively to be in 
accordance to the national guidelines without, or with minor 
deviance, in 87% of the cases. The treatment planning was in 
accordance with the guidelines for indication, treatment 
technique and lung delineation in 98% of the cases, with 
minor deviations in 2%. For delineation of the clinical target 
volume (CTV) and the heart, minor deviations were found in 
44% of the cases, major deviations in 6%. 
The dose distribution to the CTV was in accordance with the 
guidelines in 89% of cases, with minor deviations in 11%. A 
minimum dose to CTV (breast/breast wall) of at least 95% of 
prescribed dose (D98% ≥95%) was attained in 39%, whereas D98% 
≥90% was attained in 93% of the cases. 
Conclusions: The audits showed that for a large majority of 
cases, the radiotherapy was planned in accordance to the 
guideline principles. To define and delineate the target 
volumes and the heart, and to obtain optimal dose 
distributions are challenging tasks, for which improvements 
are still desirable.  
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Purpose/Objective: With the rapid growth of health 
expenditure, economic data have received increasing 
importance as source of information for decision makers. This 
is also true in technology-intensive sectors, such as 
radiotherapy, where initial capital investment is large and 
human resources important. To understand and quantify the 
evolution of radiotherapy costs it is necessary to be clear on 
which resources are included and how they have been 
combined to compute the cost. 
Materials and Methods: A systematic literature review on 
cost computation studies in radiation therapy from 2002-2013 
was conducted on Medline and Embase with the following 
search criteria: population: focus on external beam 
radiotherapy (EBRT); intervention: costing exercise using the 
departmental perspective and including at least personnel 
and equipment costs; outcome: cost of either radiotherapy 
treatment, activity or fraction(s), and/or cost of an entire 
radiotherapy department and/or cost of a specific cancer 
type including treatment with EBRT. To be included the 
article had to accurately describe the costing methodology. 
Computation studies based on charges and reimbursement 
were excluded. 
Results: Of the 961 retrieved studies only 15 matched our 
search criteria, reasons for exclusion are as shown by the 
flowchart (fig 1). The most important reason for exclusion 
was the lack of formal cost computation (n=511) in the first 
